3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
11
Neoplasms
2
Mycosis Fungoides
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphomatoid Papulosis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
5
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Biopsy
4
Nivolumab
3
sodium-iodide symporter
2
fludarabine
2
cemiplimab
2
X-Rays
2
Whole-Body Irradiation
2
Stem Cell Transplantation
2
Photons
2
Mycophenolic Acid
2
Immunoglobulin G
2
Disulfides
2
Cyclosporine
2
10-propargyl-10-deazaaminopterin
2
treosulfan
1
talimogene laherparepvec
1
sargramostim
1
ruxolitinib
1
pembrolizumab
1
fludarabine phosphate
1
entrectinib
1
duvelisib
1
ceritinib
1
belinostat
1
alectinib
1
Vincristine
1
Vinblastine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large-Cell, Anaplastic
×
Brentuximab Vedotin
×
90 days
×
Clear all
NCT07013565
2026-05-20
ACCELERATE
New York Medical College
Phase 2
Recruiting
20 enrolled